Navigation Links
Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
Date:12/20/2011

CAMBRIDGE, England, December 21, 2011 /PRNewswire/ --

Arecor Limited has entered into a collaboration agreement with Eli Lilly and Company to assess Arecor's advanced protein formulation technologies for possible use with Lilly's growing pipeline of biological-based drugs.  Under this agreement, Arecor will develop stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly.  In addition, Arecor will work with Lilly to potentially offer improved formulations of Lilly's existing therapeutic proteins in several therapeutic areas.  

Tom Saylor, CEO of Arecor, stated, "The next generation of protein and peptide therapeutics present significant formulation challenges. Arecor's stabilization tools may enable new products and presentations, which would otherwise not be possible, without additional processing or changes to standard manufacturing practices.  Lilly's strong support of innovation and emerging technologies offers Arecor the potential to apply Arecor's broad-ranging expertise in biomolecule stabilization to a leader in pharmaceutical application of the next generation of biologics."

Arecor is a pioneer in the stabilization of biologic molecules, a key challenge in the development of many therapeutic proteins, vaccines and diagnostics. Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into interactions between proteins and their immediate environment. Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products. Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation. As a simple reformulation, Arestat™ can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.

Contact:

Tom Saylor, CEO
tsaylor@arecor.com
Arecor Limited
2 Cambridge Science Park
Cambridge, UK
http://www.arecor.com


'/>"/>
SOURCE Arecor
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuse Science Announces the Launch of its Analgesic and Diabetic Oral Fuse Delivery (OFD) Research Project Platforms
2. Enlight Biosciences Forms New Partnerships with AstraZeneca and Novo Nordisk
3. Diablo Valley Oncology Performs Breast Intraoperative Radiation Procedure - First in the East Bay
4. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
5. ArjoHuntleigh Forms New Division to Enhance the Quality Home Medical Care
6. Digital ArtForms Debuts iMedic3D, a Radically Different Approach to Radiology, at RSNA ‘11, and Announces the Addition of Dr. Eliot Siegel and Dr. David Kim to Its Advisory Board Members
7. Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms
8. Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA
9. ContinuumRx Forms Healthcare Joint Venture with Mississippi Baptist Health Systems
10. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
11. Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)...  Astellas Pharma Inc. President and Chief Executive Officer ... Robinson as president, Americas Operations, for Astellas US LLC, ... South America , effective April 1, 2016.  Robinson ... organization in the United States -- ... Yoshida , who is retiring in June 2016.  ...
(Date:2/8/2016)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced ... Food and Drug Administration (FDA) on February 4, 2016, ... on the clinical studies being conducted under the Company,s ... hold impacts part of the clinical work currently being ... clinical trials. --> ...
(Date:2/5/2016)... Feb. 5, 2016  Redwood Scientific Technologies, Inc. announced ... designed to help women balance their hormones. This product ... Jason Cardiff , President and CEO. ... to help the millions of women across the country ... of imbalanced hormones. Our research and development team is ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... , ... Delta Dental of California and its affiliated companies announced today that ... who recently retired as president and CEO of Delta Dental of California and its ... Year , helped lead the effort to raise funds for studies to strengthen pancreatic ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to a product from ... a cluster of melanin when exposed to sunlight. Although most moles are benign and ... embarrassment. Historically, mole removal has involved a painful, often expensive visit to ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... four states in the U.S. require dental technicians to be certified or obtain ... dental industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
Breaking Medicine News(10 mins):